The biotech sector faces significant volatility as rising interest rates and energy prices weigh on the XBI index, shifting focus back to macroeconomic sensitivity. Regulatory stability emerges with the permanent appointments of Michael Davis to CDER and Kareem to CBER, signaling a transition toward more predictable agency leadership. Clinical data reveals mixed outcomes: Novartis faces setbacks with negative Lp(a) and DM1 trial results, prompting activist scrutiny over its acquisition strategy, while Roivant reports promising phase two data in PHILD, accelerating its phase three development. Meanwhile, the industry debates the efficacy of oral amylin therapies and the strategic trade-offs between high-cost, late-stage acquisitions and early-stage internal development. These developments underscore the ongoing challenges in cardiovascular drug development and the high bar for clinical success in specialized therapeutic areas.
Sign in to continue reading, translating and more.
Open full episode in Podwise